Cooper Companies Inc (COO) Reports Strong Q4 2025 Earnings
Cooper Companies Inc (COO) exceeded Q4 2025 earnings expectations.
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 16,000 full-time employees. The firm operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. The company also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Cooper Companies Inc.
Last Updated: Nov 18, 2025, 11:13 PM · Source: Finnhub.io
Cooper Companies Inc (COO) exceeded Q4 2025 earnings expectations.
Citigroup has downgraded Cooper Companies Inc (COO) to Neutral from Buy.
Wells Fargo has downgraded Cooper Companies Inc (COO) to Equal-Weight.